Dividend
-
-
-
-
-
-
-
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
-
-
-
-
-
-
-
Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis
-
445,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

